Literature DB >> 16702522

Primary hyperaldosteronism: effect of adrenal vein sampling on surgical outcome.

Fiemu E Nwariaku1, Barbra S Miller, Richard Auchus, Shelby Holt, Lori Watumull, Bart Dolmatch, Shawna Nesbitt, Wanpen Vongpatanasin, Ronald Victor, Frank Wians, Edward Livingston, William H Snyder.   

Abstract

HYPOTHESIS: Adrenal vein sampling is superior to computed tomography for subtype differentiation of primary hyperaldosteronism.
DESIGN: Retrospective review.
SETTING: University medical center. PATIENTS: Forty-eight patients (32 men and 16 women) with biochemically confirmed primary hyperaldosteronism. MAIN OUTCOME MEASURES: We compared demographic factors, results of biochemical and imaging studies (computed tomography and adrenal vein sampling), therapy, and patient outcomes.
RESULTS: Mean +/- SEM adrenal nodule size was 1.54 +/- 0.2 cm. Adrenal vein sampling was performed in 41 (85%) of 48 patients, and it was successful in 39 (95%) of those 41 patients. Concordance between computed tomography and adrenal vein sampling was observed in 22 (54%) of the 41 patients. Thirty-two patients underwent successful laparoscopic adrenalectomy. There was 1 complication and no deaths. All 32 patients were cured of hypokalemia.
CONCLUSION: Adrenal vein sampling is superior to image-based techniques for subtype differentiation of primary hyperaldosteronism.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16702522     DOI: 10.1001/archsurg.141.5.497

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  41 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

2.  Effect of age on aldosterone/renin ratio (ARR) and comparison of screening accuracy of ARR plus elevated serum aldosterone concentration for primary aldosteronism screening in different age groups.

Authors:  Guoshu Yin; Shaoling Zhang; Li Yan; Muchao Wu; Mingtong Xu; Feng Li; Hua Cheng
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  A patient with concurrent primary aldosteronism and Page kidney.

Authors:  Chin-Chi Kuo; Huan-Lun Hsu; Chao-Yuan Huang; Kao-Lang Liu; Vin-Cent Wu; Ching-Wei Tsai; Wei-Jie Wang
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

Review 4.  Primary aldosteronism.

Authors:  Richard J Auchus; Fiemu E Nwariaku
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

5.  Retroperitoneoscopic adrenalectomy in Conn's syndrome caused by adrenal adenomas or nodular hyperplasia.

Authors:  Martin K Walz; Roland Gwosdz; Stephanie L Levin; Piero F Alesina; Anna-Carinna Suttorp; Klaus A Metz; Frank A Wenger; Stephan Petersenn; Klaus Mann; Kurt W Schmid
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

Review 6.  Resistant hypertension and aldosteronism.

Authors:  Eduardo Pimenta; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

7.  Adrenal vein sampling may not be a gold-standard diagnostic test in primary aldosteronism: final diagnosis depends upon which interpretation rule is used. Variable interpretation of adrenal vein sampling.

Authors:  Gregory A Kline; Adrian Harvey; Charlotte Jones; Michael H Hill; Benny So; Nairne Scott-Douglas; Janice L Pasieka
Journal:  Int Urol Nephrol       Date:  2008-08-12       Impact factor: 2.370

Review 8.  Primary aldosteronism and a Texas two-step.

Authors:  Richard J Auchus
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 9.  Resistant hypertension and hyperaldosteronism.

Authors:  Carolina C Gonzaga; David A Calhoun
Journal:  Curr Hypertens Rep       Date:  2008-12       Impact factor: 5.369

Review 10.  Differential diagnosis of primary aldosteronism subtypes.

Authors:  Paolo Mulatero; Chiara Bertello; Andrea Verhovez; Denis Rossato; Giuseppe Giraudo; Giulio Mengozzi; Giorgio Limerutti; Eleonora Avenatti; Davide Tizzani; Franco Veglio
Journal:  Curr Hypertens Rep       Date:  2009-06       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.